About Lysosomal acid phosphatase
Lysosomal acid phosphatase (ACP2) is a protein
from Homo sapiens identified by UniProt accession
P11117, 423 residues long.
MolForge cross-references it against 0 known binders and
261 disease associations.
Target properties
| Protein name | Lysosomal acid phosphatase |
| UniProt accession | P11117 |
| Gene | ACP2 |
| Organism | Homo sapiens |
| Length | 423 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (261)
Diseases linked to this target (Open Targets).
- high density lipoprotein cholesterol measurement · score 0.32
- triglyceride measurement · score 0.27
- sleep duration · score 0.25
- C-reactive protein measurement · score 0.23
- serum urea measurement · score 0.21
- IGF-1 measurement · score 0.21
- HDL cholesterol change measurement · score 0.20
- physical activity · score 0.20
- neurodegenerative disease · score 0.20
- apolipoprotein A 1 measurement · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P11117-F1 | alphafold | PREDICTED | 91.63 | — |
Amino-acid sequence (423 residues)
MAGKRSGWSR AALLQLLLGV NLVVMPPTRA RSLRFVTLLY RHGDRSPVKT YPKDPYQEEE WPQGFGQLTK EGMLQHWELG QALRQRYHGF LNTSYHRQEV YVRSTDFDRT LMSAEANLAG LFPPNGMQRF NPNISWQPIP VHTVPITEDR LLKFPLGPCP RYEQLQNETR QTPEYQNESS RNAQFLDMVA NETGLTDLTL ETVWNVYDTL FCEQTHGLRL PPWASPQTMQ RLSRLKDFSF RFLFGIYQQA EKARLQGGVL LAQIRKNLTL MATTSQLPKL LVYSAHDTTL VALQMALDVY NGEQAPYASC HIFELYQEDS GNFSVEMYFR NESDKAPWPL SLPGCPHRCP LQDFLRLTEP VVPKDWQQEC QLASGPADTE VIVALAVCGS ILFLLIVLLL TVLFRMQAQP PGYRHVADGE DHA
Explore Lysosomal acid phosphatase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets